Stockhead’s Ashtyn Hiron sits down with EZZ Life Science (ASX:EZZ) chairman and non-executive director Glenn Cross to close the books on 2023 and gain a sneak peek into what’s around the corner.

“FY23 was a great result for us across the board,” Cross said.

“We increased our revenue to $37.1 million, up 147% on the previous year, which was mainly attributed to our increased sales volume in China.”

Tune in to hear what’s coming up for EZZ Life Science in 2024.

Read MoreHealth

Featured Companies

You might be interested in